2010-present - Postdoctoral Research Scientist, Department of Psychology, Columbia University; Advisor: Dr. Frances Champagne.
2009-2010 - Postdoctoral Research Fellow, Gene Regulation Program, Centre for Genomic Regulation, Barcelona, Spain;
Project: The role of DNA methylation and DNA methyltransferases in the regulation of progesterone target genes; Advisor: Dr. Miguel Beato.
2003-2008 - Ph.D., Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago;
Thesis: Epigenetic mechanisms in the regulation of the reelin and glutamic acid decarboxylase 67 genes; Advisor: Dr. Dennis R. Grayson.
2001-2003 - M.Sc., Experimental Pharmacology; School of Medicine, University of Belgrade, Serbia;
Thesis: Serotonergic and dopaminergic activity of several novel heterocyclic arylpiperazines; Advisors: Dr. Mirko Tomic and Dr. Milica Prostran.
1995-2001 - PharmD, School of Pharmacy, University of Belgrade, Serbia.
Kundakovic M, Lim S, Gudsnuk K, Champagne FA, 2013, Sex-specific and strain-dependent effects of early life adversity on behavioral and epigenetic outcomes. Front Psychiatry 4:78.
Kundakovic M, Gudsnuk K, Franks B, Madrid J, Miller RL, Perera FP, Champagne FA, 2013, Sex-specific epigenetic disruption and behavioral changes following low-dose in utero bisphenol A exposure. Proceedings of the National Academy of Sciences USA 110(24):9956-61.
Kirkbride JB, Susser E, Kundakovic M, Kresovich JK, Davey Smith G, Relton CL, 2012, Prenatal nutrition, epigenetics and schizophrenia risk: Can we test causal effects? Epigenomics4(3): 303-315
Kundakovic M & Champagne FA, 2011, Epigenetic Perspective on the Developmental Effects of Bisphenol A, Brain, Behavior & Immunity 25: 1084-93.
Grayson DR, Kundakovic M, and Sharma RP, 2010, Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol 77: 126-35.
Kundakovic M, Chen Y, Guidotti A, and Grayson DR, 2009, The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. Mol Pharmacol 75: 342-54.
Grayson DR, Chen Y, Dong E, Kundakovic M, Guidotti A, 2009, From trans-methylation to cytosine methylation: evolution of the methylation hypothesis of schizophrenia. Epigenetics 4:144-9.
Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, and Costa E, 2009, Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci 30:55-60.
Costa E, Chen Y, Dong E, Grayson DR, Kundakovic M, Maloku E, Ruzicka W, Satta R, Veldic M, Zhubi A, and Guidotti A, 2009, GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability. Expert Rev Neurother 9:87-98.
Kundakovic M, Chen Y, Costa E, Grayson DR, 2007, DNA Methyltransferase Inhibitors Coordinately Induce Expression of the Human Reelin and Glutamic Acid Decarboxylase 67 Genes. Mol Pharmacol 71: 644-53.
* this article is a featured article in the March 2007 issue of Molecular Pharmacology; (commentary by Levenson JM: DNA (Cytosine-5) Methyltransferase Inhibitors: A Potential Therapeutic Agent for Schizophrenia. Mol Pharmacol 71: 635-37).
Chen Y, Kundakovic M, Agis-Balboa RC, Pinna G, Grayson DR, 2007, Induction of the reelin promoter by retinoic acid is mediated by Sp1. J Neurochem 103: 650-65.
Grayson DR, Chen Y, Costa E, Dong E, Guidotti A, Kundakovic M, Sharma RP, 2006, The human reelin gene: transcription factors (+), repressors (-) and the methylation switch (+/-) in schizophrenia. Pharmacol Ther 111:272-86.
Mitchell CP, Chen Y, Kundakovic M, Costa E, Grayson DR, 2005, Histone deacetylase inhibitors decrease reelin promoter methylation in vitro. J Neurochem 93:483-92.
Tomic M, Kundakovic M, Butorovic B, Janac B, Andric D, Roglic G, Ignjatovic D, Kostic-Rajacic S, 2004, Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential. Bioorg Med Chem Lett 14:4263-6.
Tomic M, Kundakovic M, Butorovic B, Vasilev V, Dragovic D, Roglic G, Ignjatovic DJ, Soskic V, Kostic-Rajacic S, 2003, Pharmacological evaluation of 5-[2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethyl]-1,3-dihydro-benzimidazole-2-thione as a potential atypical antipsychotic agent. Pharmazie 58:677-8.
Department of Psychology
406 Schermerhorn Hall
1190 Amsterdam Ave
email: Dr Marija Kundakovic